HE-S2 

HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity^[1].

PD-1/PD-L1 and TLR7/8 ^[1]

HE-S2 (10 ng; 30 min) effectively targets and binds with PD-L1in MC38 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

787.95

C₃₈H₄₅N₉O₆S₂

2939851-67-7

C[C@H](COC(NC1=CC=C(C[N+](C)(C)CC2=CC=C(CC3=CC=C(N=C(N)N=C4NCCCC)C4=N3)C=C2)C=C1)=O)SSC5=NC=C([N+]([O-])=O)C=C5.[H]C([O-])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64(21):15716-15726.  [Content Brief]